Affimed N.V. is part of the healthcare sector and is part of the biotechnology industry. The company CEO is Adi Hoess. Affimed NV is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology to fight tumor cells.

Previous Intraday Performance:

The AFMD shares had a previous change of -4.59% which opened at 4.15 and closed at 3.95. It moved to an intraday high of 4.16 and a low of 3.92.

SeekingAlpha:  LULU, AMRN and FIVE among premarket gainers

Historical Performance:

Over the last five trading days, AFMD shares returned -1.99% and in the past 30 trading days it returned 8.22%. Over three months, it changed 13.83%. In one year it has changed 85.88% and within that year its 52-week high was 7.35 and its 52-week low was 1.40. AFMD stock is 182.14% above its 52 Week Low.

Our calculations result in a 200 day moving average of 3.37 and a 50 day moving average of 3.78. Right now, AFMD stock is trading 17.19% above its 200 day moving average.

SeekingAlpha:  LULU, AMRN and FIVE among premarket gainers


The company has a market cap of $246.6m with 62.4m shares outstanding and a float of 62.4m shares. Trading volume was 1,147,207 shares and has experienced an average volume of 1,240,899 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Affimed N.V. was -0.37 which ended on 31st of December 2018. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.16.

Base on our calculations, the intrinsic value per share is 8.32, which means it might be undervalued and has a margin of safety of 52.55%

The next earnings report will be: 05-08-2019

The long-term trend of the EPS is an important number as it indicates the present value of Affimed N.V.; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 725.90% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 57.40% of institutional ownership.

I calculated the beta to be 3.33

SeekingAlpha:  Carlyle Group to buy 30% stake in Spanish oil and gas firm Cepsa – FT

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -53.28%, return on assets is -24.16%, profit margin is -46.08%, price-to-sales is 9.71 and price-to-book is 5.46.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here